B-Cell Lymphoma ADCT 402-311
Study #402-311A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5).
Description
The purpose of B-Cell Lymphoma ADCT 402-311 is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
Sponsor: ADC Therapeutics S.A.
Principal Investigator: Dr. Tara Graff